VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
-5.31%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$353M
AUM Growth
+$353M
(+28%)
Cap. Flow
+$126M
Cap. Flow
% of AUM
35.75%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
1
Reduced
1
Closed
–
Top Buys
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$115M |
| 2 |
Ventyx Biosciences
VTYX
|
$11.6M |
Top Sells
| 1 |
SLRN
ACELYRIN
SLRN
|
$48.4K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RYZB
1
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $115M | 32.47% | +5,158,162 | New | +$115M |
|
2
Pharvaris
PHVS
$1.39B
| $89M | 25.24% | 4,264,672 | – | – |
|
3
ALX Oncology
ALXO
$62.7M
| $46.6M | 13.2% | 9,699,925 | – | – |
|
|
SLRN
4
DELISTED
ACELYRIN
SLRN
| $39.2M | 11.11% | 3,852,470 -4,760 | -0.1% | -$48.4K |
|
5
Harmony Biosciences
HRMY
$2.12B
| $33.9M | 9.62% | 1,035,396 | – | – |
|
|
6
Ventyx Biosciences
VTYX
$171M
| $26.4M | 7.47% | 758,800 +334,768 | +79% | +$11.6M |
|
|
ELEV
7
DELISTED
Elevation Oncology
ELEV
| $1.93M | 0.55% | 2,914,255 | – | – |
|
|
IMPL
8
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $1.19M | 0.34% | 2,759,791 | – | – |
|